Moreover, in the phase 2b MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF) the investigators found a lower incidence of the clinical composite endpoint (all-cause death, cardiovascular hospitalization or emergency presentation for worsening chronic heart failure) among patients treated with finerenone compared with eplerenone, even though the study was not powered for this observation [12]. The gene discussed is NR3C2; the disease is heart failure.